MedTrace Logo

NEWS2+Procalcitonin Association in Patients With Infection and Its Significance in Oncological Patients

NCT06761118 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1041

Last updated 2025-01-07

No results posted yet for this study

Summary

This observational study aims to evaluate the prognostic significance of the combination of a clinical score (specifically, a score obtained through the measurement of multiple parameters such as blood pressure, body temperature, etc., typically assessed during triage), called NEWS2, with certain laboratory tests in patients presenting with a suspected infection to our Emergency Department. We decided to conduct this study because the presentation symptoms of an infection are varied and sometimes subtle, making it very difficult to immediately recognize an infection in patients arriving at the Emergency Department. It is even more challenging to identify those at higher risk for negative clinical outcomes. However, it has been shown that rapid identification and early, targeted therapy significantly improve prognosis, increasing the chances of patient recovery.

The study aims to identify a tool that can help physicians to early recognize patients with infection, particularly those at higher risk for an unfavorable course. To this end, we are evaluating the effectiveness of combining a clinical score, called NEWS2, with a laboratory parameter (procalcitonin).

It is anticipated that approximately 1,000-1,200 people will participate in this study over the course of one year.

The study plans to involve all patients presenting to the Emergency Department with a suspected infection. The diagnostic and therapeutic process will remain unchanged from the standard clinical practice applied according to international guidelines, and no follow-up assessments will be required in the subsequent months

Conditions

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Antonella Viola, MD · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06761118 on ClinicalTrials.gov